The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The proposed cuts have caused concerns among some Senate Republicans, including Utah Sen. John Curtis, who may consider ...

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...

As HIV cases continue to rise in the Philippines, especially among the youth, a new global development may offer hope in ...

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

Lenacapavir, which was approved by the United States' Food and Drug Administration in June this year, is taken twice per year ...

Global Fund aims for the first shipment to reach at least one African country by year-end. Read more at straitstimes.com.

(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

For John, a 19-year-old from rural Mississippi, getting medication to prevent HIV came with more than just a prescription — it came with fear.